DRAP Joins Regulators to Strengthen Medicine Monitoring

DRAP has joined hands with provincial and state drug regulators to strengthen the monitoring of medicines and other medical products across Pakistan. A three-day workshop, supported by the WHO, was part of that work.

In this article we set out what the workshop focused on. Here is everything you need to know.

What DRAP and the regulators focused on

The workshop covered risk-based sampling, digital monitoring tools, and better coordination. Those steps are meant to help detect counterfeit and substandard products and to protect public health. The update does not name the city, the dates of the three days, or a new law.

Why it matters

Monitoring medicines is a job shared by DRAP and the provincial and state regulators. Sampling, digital tools and coordination are the three methods the workshop put in front of them, with WHO support, against counterfeit and substandard products.

• DRAP is working with provincial and state drug regulators
• The goal is stronger monitoring across Pakistan
• Medicines and other medical products are both covered
• The WHO supported a three-day workshop
• The topics were risk-based sampling, digital tools and coordination
• The target is counterfeit and substandard products

What this update leaves open

1. The city where the workshop was held.
2. The three dates.
3. A new penalty or a new law.
4. How many products were sampled.

What happens next

The regulators are to use risk-based sampling, digital tools and closer coordination in monitoring. We will update this article if DRAP publishes a sampling result or a schedule.

Our verdict

DRAP has joined provincial and state drug regulators to strengthen medicine monitoring, after a WHO-backed workshop on sampling, digital tools and coordination against counterfeit and substandard products.

Follow for more updates.